Trials 44 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05915949 Comparator | Jan 2022 → Oct 2023 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02338921 Comparator | Jan 2015 → Nov 2021 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02315287 Comparator | Sep 2014 → Dec 2021 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 48 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lobeglitazone | “This is a Phase 1, single-center, parallel group study designed to determine the single-dose safety and PK profile of lobeglitazone from M107 ODT and Duvie, both administered...” NCT07056517 ↗17“PURPOSE: Lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, is metabolized primarily by the cytochrome P450 (CYP) 3A4 isoenzyme.” PMID 25047497 ↗ Jul 2014 “An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.” PMID 32362346 ↗ Apr 2020 “0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy” NCT03770052 ↗ “Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg” NCT04869800 ↗ “Efficacy and Safety of Lobeglitazone Versus Sitagliptin” NCT02480465 ↗ “metformin+sitagliptin (Januvia)+lobeglitazone (Duvie)” NCT02188186 ↗ “Lobeglitazone Sulfate 0.5mg, Metformin HCl 1000mg” NCT02565368 ↗ “1. D308 2. CKD-501: Lobeglitazone sulfate 0.5mg” NCT03616392 ↗ “Lobeglitazone, Empagliflozin, Metformin” NCT06492655 ↗ |
| Known as | CKD-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05347576 ↗24 |
| Known as | CKD-501 : Lobeglitazone | “CKD-501 : Lobeglitazone” NCT01133431 ↗ |
| Known as | Duvie | “0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy” NCT03770052 ↗4“we investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD.” PMID 27914133 ↗ Jan 2017 “metformin+sitagliptin (Januvia)+lobeglitazone (Duvie)” NCT02188186 ↗ |
| Known as | Lobeglitazona | ChEMBL registry synonym — accepted as the source's own label CHEMBL3585580 ↗ |
| Known as | lobeglitazone sulfate | “1 tablet of lobeglitazone sulfate (0.5 mg) once daily for 5 days” PMID 32362346 ↗ Apr 20202“Lobeglitazone Sulfate 0.5mg, Metformin HCl 1500mg” NCT02627027 ↗ “1. D308 2. CKD-501: Lobeglitazone sulfate 0.5mg” NCT03616392 ↗ |
| Action | Activate | “CKD-501 is highly selective peroxisome proliferator-activated receptor-gamma agonist” NCT01001611 ↗ |
| Modality | Small molecule | “Lobeglitazone, a Novel Thiazolidinedione” PMID 27914133 ↗ Jan 2017 |
| Route | Oral | “0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)” NCT01001611 ↗ |
| Target | PPARG | “Lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist” PMID 25047497 ↗ Jul 2014 |